#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15150	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2140	704.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1471	1471	C	810	C	749	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3575	785.4	0	.	n	.	0	T695C	SNP	695	695	T	1030	1030	C	829	C,G,T	778,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3575	785.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1672	1672	A	938	A	873	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3575	785.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2306	2306	C	923	C,T	851,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3575	785.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2932	2932	T	897	T	841	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28162	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3575	785.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2380	2380	A	918	A	861	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2074	folP	852	852	100.0	folP.l15.c4.ctg.1	1533	134.4	1	SNP	p	R228S	1	.	.	682	684	AGC	978	980	AGC	211;215;215	A;G;C,A	202;205;202,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5488	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3393	161.1	1	SNP	p	S91F	0	.	.	271	273	TCC	597	599	TCC	168;168;168	T;C,T;C	157;156,1;155	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5488	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3393	161.1	1	SNP	p	D95G	0	.	.	283	285	GAC	609	611	GAC	166;167;168	G;A,G;C	161;158,1;160	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5488	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3393	161.1	1	SNP	p	D95N	0	.	.	283	285	GAC	609	611	GAC	166;167;168	G;A,G;C	161;158,1;160	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1720	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1526	112.5	1	SNP	p	G45D	1	.	.	133	135	GAC	609	611	GAC	214;214;218	G;A,G;C,A	201;198,1;204,1	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	884	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	950	91.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5434	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3045	177.9	1	SNP	p	D86N	0	.	.	256	258	GAC	616	618	GAC	218;218;218	G;A,G;C	202;199,1;204	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5434	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3045	177.9	1	SNP	p	S87W	0	.	.	259	261	AGT	619	621	AGT	218;218;219	A;G;T	203;202;201	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5434	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3045	177.9	1	SNP	p	S87I	0	.	.	259	261	AGT	619	621	AGT	218;218;219	A;G;T	203;202;201	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5434	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3045	177.9	1	SNP	p	S87R	0	.	.	259	261	AGT	619	621	AGT	218;218;219	A;G;T	203;202;201	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5434	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3045	177.9	1	SNP	p	S88P	0	.	.	262	264	TCC	622	624	TCC	221;224;223	T,G;C;C	202,1;205;203	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4744	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2564	183.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1521	1523	GGC	214;213;211	G;G;C	192;187;183	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1274	1276	GCA	247;250;256	G,A;C;A	227,1;230;240	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1277	1279	ATC	259;259;259	A;T;C	242;241;242	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1289	1291	GTG	254;251;251	G;T;G	239;231;234	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1289	1291	GTG	254;251;251	G;T;G	239;231;234	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1793	1795	ACC	204;203;201	A;C;C	186;190;187	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1847	1849	GCG	184;182;181	G;C;G	155;141;152	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1847	1849	GCG	184;182;181	G;C;G	155;141;152	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1970	1972	GGC	175;168;166	G;G;C	163;154;154	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1979	1981	GGC	162;158;159	G;G;C	145;140;136	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2444	164.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1997	1999	CCG	130;132;132	C,G;C;G,GT	105,6;106;107,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5994	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	2990	199.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1485	1487	CTG	242;243;245	C;T,C;G	217;215,1;216	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2422	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1868	128.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	564	564	C	192	C	175	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	363	90.19	porB1a.l15.c4.ctg.2	586	21.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	127	129	AAT	15;15;15	A;A;T	15;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	363	90.19	porB1a.l15.c4.ctg.2	586	21.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	130	132	AAT	15;15;15	A;A;T	15;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	363	90.19	porB1a.l15.c4.ctg.2	586	21.7	0	.	p	.	0	A222V	NONSYN	664	666	GCT	142	144	GTT	19;19;19	G;T;T	19;19;19	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	363	90.19	porB1a.l15.c4.ctg.2	586	21.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	154	156	GCA	21;21;21	G;C;A	20;21;21	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	363	90.19	porB1a.l15.c4.ctg.2	586	21.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	177	179	GTA	20;21;21	G;T;A	20;21;21	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	272	porB1a	984	363	90.19	porB1a.l15.c4.ctg.2	586	21.7	0	.	p	.	0	D238fs	FSHIFT	712	712	G	189	189	G	24	G	24	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	G38E	NONSYN	112	114	GGA	395	397	GAA	251;249;248	G;A;A	230;231;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	S46G	NONSYN	136	138	AGC	419	421	GGC	228;223;222	G;G;C	217;212;212	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	425	427	GGA	222;220;220	G;G;A	205;202;204	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	542	544	GCT	230;235;237	G,A;C;T,C	212,1;216;213,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	548	550	AGC	239;239;243	A;G;C	216;218;214	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	640	641	CG	222;220	C;G	208;205	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	643	645	CAG	213;213;213	C;A;G,A	202;203;203,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	647	649	AAA	212;212;212	A;A;A	204;205;205	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	710	712	GAA	212;213;211	G;A;A	191;193;187	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	734	736	GCA	215;215;214	G,A;C;A	195,1;195;193	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	842	844	CGA	250;252;252	C;G,T;A	228;227,1;232	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	A215T	NONSYN	643	645	GCT	926	928	ACT	204;204;203	A;C;T	193;193;191	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	929	931	CAT	202;200;202	C;A;T	192;187;191	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	I218M	NONSYN	652	654	ATA	935	937	ATG	205;207;206	A;T;G	195;195;194	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1049	1051	GCA	206;205;204	G;C;A	199;197;199	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1052	1054	ACG	203;204;205	A,G;C;G	196,1;199;199	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1055	1057	AGG	203;204;205	A;G;G,T	198;198;198,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1058	1060	GTT	202;205;207	G;T;T,C	195;196;200,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1118	1120	GTA	206;207;206	G;T;A	186;186;186	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1157	1159	ACT	203;208;205	A;C;T	186;192;189	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1163	1165	GAT	203;203;202	G;A;T	191;191;189	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1166	1168	GAT	206;207;207	G;A;T,C	195;195;194,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1175	1177	CAC	208;207;204	C;A;C	194;193;191	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	1	SNP	p	G120K	1	.	.	358	360	AAG	640	642	CGG	222;220;218	C;G;G	208;205;201	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	1	SNP	p	D121N	0	.	.	361	363	GAC	643	646	CGC	213;213;214	C;G,A;C	202;203,1;204	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2676	porB1b	1047	1047	96.66	porB1b.l15.c17.ctg.1	1471	181.0	1	SNP	p	A121D	1	.	.	361	363	GAC	643	646	CGC	213;213;214	C;G,A;C	202;203,1;204	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10410	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4792	216.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1943	1945	AAT	217;218;222	A,C;A;T	199,1;202;203	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1126	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1136	98.8	1	SNP	p	V57M	1	.	.	169	171	ATG	552	554	ATG	243;243;246	A;T;G	224;226;227	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
